Affinity Capital Advisors’s RenovoRx RNXT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $17K | Hold |
13,279
| – | – | ﹤0.01% | 233 |
|
|
2026
Q2 | $12.6K | Hold |
13,279
| – | – | ﹤0.01% | 203 |
|
|
2026
Q1 | $13.4K | Hold |
13,279
| – | – | ﹤0.01% | 181 |
|
|
2025
Q4 | $11.2K | Hold |
13,279
| – | – | ﹤0.01% | 173 |
|
|
2025
Q3 | $16.9K | Hold |
13,279
| – | – | ﹤0.01% | 153 |
|
|
2025
Q2 | $17.5K | Hold |
13,279
| – | – | ﹤0.01% | 158 |
|
|
2025
Q1 | $10.3K | Hold |
13,279
| – | – | ﹤0.01% | 153 |
|
|
2024
Q4 | $18.2K | Hold |
13,279
| – | – | ﹤0.01% | 150 |
|
|
2024
Q3 | $14.1K | Hold |
13,279
| – | – | ﹤0.01% | 151 |
|
|
2024
Q2 | $15K | Hold |
13,279
| – | – | ﹤0.01% | 145 |
|
|
2024
Q1 | $17.8K | Hold |
13,279
| – | – | ﹤0.01% | 150 |
|
|
2023
Q4 | $30.4K | Hold |
13,279
| – | – | 0.01% | 135 |
|
|
2023
Q3 | $17.7K | Hold |
13,279
| – | – | ﹤0.01% | 131 |
|
|
2023
Q2 | $30K | Hold |
13,279
| – | – | 0.01% | 132 |
|
|
2023
Q1 | $46.3K | Sell |
13,279
-1,980
| -13% | -$6.97K | 0.01% | 120 |
|
|
2022
Q4 | $35.9K | Buy |
15,259
+4,009
| +36% | +$7.66K | 0.01% | 106 |
|
|
2022
Q3 | $23K | Buy |
+11,250
| New | +$24.4K | 0.01% | 104 |
|
Other funds holding RNXT
Affinity Capital Advisors's RNXT Position: Q3 2026 in Review
Affinity Capital Advisors held its RenovoRx (RNXT) position steady in Q3 2026 at 13,279 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #233.
Affinity Capital Advisors first reported a position in RNXT in Q3 2022 and has held it in 17 quarters since. The position peaked at $46.3K in Q1 2023. 2 funds tracked by Wall St. Rank hold RNXT as of Q3 2026.
- Affinity Capital Advisors held 13,279 shares of RenovoRx worth $17K as of Q3 2026.
- Affinity Capital Advisors left its RenovoRx share count unchanged in Q3 2026.
- RenovoRx made up ﹤0.01% of Affinity Capital Advisors's portfolio in Q3 2026, its #233 holding.
- Affinity Capital Advisors first reported a position in RenovoRx in Q3 2022 and has held it in 17 quarters since.
- Affinity Capital Advisors's RenovoRx position peaked at $46.3K in Q1 2023.
- 2 funds tracked by Wall St. Rank held RenovoRx as of Q3 2026.
Based on Affinity Capital Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.